SAC Meeting Calendar

The SAC Tracker Background Analysis is available in this calendar until 10 days after the meeting is held.

 
 

Newest Meeting Announcements

Newest Background Analyses

Featured
Meeting Announcement FDA, CTGTAC jessica adams Comment
Meeting Announcement FDA, CTGTAC jessica adams Comment
OCT 12 CTGTAC
Meeting Announcement FDA, CTGTAC jessica adams Comment
Meeting Announcement FDA, CTGTAC jessica adams Comment

Voretigene neparvovec by Spark Therapeutics for the treatment of patients with vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy

Meeting Announcement FDA, CTGTAC jessica adams Comment
Meeting Announcement FDA, CTGTAC jessica adams Comment
Meeting Announcement FDA, BRUDAC jessica adams Comment
Meeting Announcement FDA, BRUDAC jessica adams Comment
DEC 7 BRUDAC
Meeting Announcement FDA, BRUDAC jessica adams Comment
Meeting Announcement FDA, BRUDAC jessica adams Comment

Trial designs for drugs to treat interstitial cystitis and bladder pain syndrome

Meeting Announcement FDA, BRUDAC jessica adams Comment
Meeting Announcement FDA, BRUDAC jessica adams Comment
Featured
Background Analysis FDA, VRBPAC jessica adams Comment
Background Analysis FDA, VRBPAC jessica adams Comment
OCT 4 VRBPAC
Background Analysis FDA, VRBPAC jessica adams Comment
Background Analysis FDA, VRBPAC jessica adams Comment

Recommendations on the selection of strains to be included in an influenza virus vaccine for the 2018 Southern Hemisphere influenza season

Background Analysis FDA, VRBPAC jessica adams Comment
Background Analysis FDA, VRBPAC jessica adams Comment
Background Analysis FDA, BRUDAC jessica adams Comment
Background Analysis FDA, BRUDAC jessica adams Comment
DEC 7 BRUDAC
Background Analysis FDA, BRUDAC jessica adams Comment
Background Analysis FDA, BRUDAC jessica adams Comment

Trial designs for drugs to treat interstitial cystitis and bladder pain syndrome

Background Analysis FDA, BRUDAC jessica adams Comment
Background Analysis FDA, BRUDAC jessica adams Comment

Newest Briefing Summaries

Newest Results Wires

Featured
Briefing Summary FDA, ODAC jessica adams Comment
Briefing Summary FDA, ODAC jessica adams Comment
SEP 19 ODAC
Briefing Summary FDA, ODAC jessica adams Comment
Briefing Summary FDA, ODAC jessica adams Comment

sNDA for SUTENT (sunitinib malate), represented by Pfizer, Inc. (authorized U.S. agent), proposed for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.

Briefing Summary FDA, ODAC jessica adams Comment
Briefing Summary FDA, ODAC jessica adams Comment
Briefing Summary FDA, AADPAC, DSRM jessica adams Comment
Briefing Summary FDA, AADPAC, DSRM jessica adams Comment
SEP 14 AADPAC-DSRM
Briefing Summary FDA, AADPAC, DSRM jessica adams Comment
Briefing Summary FDA, AADPAC, DSRM jessica adams Comment

Review of pediatric study of Butrans (buprenorphine transdermal) by Purdue Pharma L.P. for management of pain

Briefing Summary FDA, AADPAC, DSRM jessica adams Comment
Briefing Summary FDA, AADPAC, DSRM jessica adams Comment
Featured
Results Wire FDA, ODAC jessica adams Comment
Results Wire FDA, ODAC jessica adams Comment
SEP 19 ODAC
Results Wire FDA, ODAC jessica adams Comment
Results Wire FDA, ODAC jessica adams Comment

sNDA for SUTENT (sunitinib malate), represented by Pfizer, Inc. (authorized U.S. agent), proposed for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.

Results Wire FDA, ODAC jessica adams Comment
Results Wire FDA, ODAC jessica adams Comment
Results Wire FDA, AADPAC, DSRM jessica adams Comment
Results Wire FDA, AADPAC, DSRM jessica adams Comment
SEP 14 AADPAC-DSRM
Results Wire FDA, AADPAC, DSRM jessica adams Comment
Results Wire FDA, AADPAC, DSRM jessica adams Comment

Review of pediatric study of Butrans (buprenorphine transdermal) by Purdue Pharma L.P. for management of pain

Results Wire FDA, AADPAC, DSRM jessica adams Comment
Results Wire FDA, AADPAC, DSRM jessica adams Comment

Search by Tag